Log In
Print
BCIQ
Print
Print this Print this
 

ALN-PCSsc

  Manage Alerts
Collapse Summary General Information
Company Alnylam Pharmaceuticals Inc.
DescriptionSubcutaneous formulation of small interfering RNA (siRNA) against proprotein convertase subtilisn/kexin type 9 (PCSK9)
Molecular Target Proprotein convertase subtilisin/kexin type 9 (PCSK9)
Mechanism of Action 
Therapeutic ModalityNucleic acid: Linear RNA: siRNA
Latest Stage of DevelopmentPhase I
Standard IndicationHypercholesterolemia
Indication DetailsTreat hypercholesterolemia; Treat severe hypercholesterolemia
Regulatory Designation

Partner

The Medicines Co.


 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

$205.0M

$25.0M

$180.0M


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone
Get a free BioCentury trial today